494 related articles for article (PubMed ID: 19573559)
21. Stable expression of chimeric anti-CD3 receptors on mammalian cells for stimulation of antitumor immunity.
Liao KW; Chen BM; Liu TB; Tzou SC; Lin YM; Lin KF; Su CI; Roffler SR
Cancer Gene Ther; 2003 Oct; 10(10):779-90. PubMed ID: 14502231
[TBL] [Abstract][Full Text] [Related]
22. Construction and characterization of a novel fusion protein consisting of anti-CD3 antibody fused to recombinant interleukin-2.
Lee KD; Chen HW; Chen CC; Shih YC; Liu HK; Cheng ML
Oncol Rep; 2006 May; 15(5):1211-6. PubMed ID: 16596189
[TBL] [Abstract][Full Text] [Related]
23. Anti-CD3:anti-IL-2 receptor bispecific monoclonal antibody. Targeting of activated T cells in vitro.
MacLean JA; Su Z; Guo Y; Sy MS; Colvin RB; Wong JT
J Immunol; 1993 Feb; 150(4):1619-28. PubMed ID: 8432997
[TBL] [Abstract][Full Text] [Related]
24. Transforming growth factor beta 1 (TGF-beta1) and rapamycin synergize to effectively suppress human T cell responses via upregulation of FoxP3+ Tregs.
Kawamoto K; Pahuja A; Hering BJ; Bansal-Pakala P
Transpl Immunol; 2010 May; 23(1-2):28-33. PubMed ID: 20307666
[TBL] [Abstract][Full Text] [Related]
25. Osteopontin augments CD3-mediated interferon-gamma and CD40 ligand expression by T cells, which results in IL-12 production from peripheral blood mononuclear cells.
O'Regan AW; Hayden JM; Berman JS
J Leukoc Biol; 2000 Oct; 68(4):495-502. PubMed ID: 11037970
[TBL] [Abstract][Full Text] [Related]
26. Modulation of the release of cytokines and reduction of the shock syndrome induced by anti-CD3 monoclonal antibody in mice by interleukin-10.
Donckier V; Flament V; Gérard C; Abramowicz D; Vandenabeele P; Wissing M; Delvaux A; Fiers W; Leo O; Velu T
Transplantation; 1994 May; 57(10):1436-9. PubMed ID: 8197603
[TBL] [Abstract][Full Text] [Related]
27. A humanised mouse model of cytokine release: comparison of CD3-specific antibody fragments.
Malcolm SL; Smith EL; Bourne T; Shaw S
J Immunol Methods; 2012 Oct; 384(1-2):33-42. PubMed ID: 22796190
[TBL] [Abstract][Full Text] [Related]
28. Altered production of immunoregulatory cytokines by invariant Valpha19 TCR-bearing cells dependent on the duration and intensity of TCR engagement.
Shimamura M; Huang YY; Kobayashi M; Goji H
Int Immunol; 2009 Feb; 21(2):179-85. PubMed ID: 19106232
[TBL] [Abstract][Full Text] [Related]
29. Mechanisms of immunosuppression induced by antithymocyte globulins and OKT3.
Bonnefoy-Berard N; Revillard JP
J Heart Lung Transplant; 1996 May; 15(5):435-42. PubMed ID: 8771497
[TBL] [Abstract][Full Text] [Related]
30. Heart allograft acceptance induced by anti-CD3 antibody in high-responder rats: effect on foxp3 and cytokine expression and graft infiltration.
Lam VW; Taylor CF; Laurence JM; Wang C; Sharland AF; McCaughan GW; Hodgkinson S; Allen RD; Hall BM; Bishop GA
Transpl Immunol; 2008 Apr; 19(1):20-4. PubMed ID: 18346633
[TBL] [Abstract][Full Text] [Related]
31. Human gamma interferon production by leukocytes induced with monoclonal antibodies recognizing T cells.
von Wussow P; Platsoucas CD; Wiranowska-Stewart M; Stewart WE
J Immunol; 1981 Sep; 127(3):1197-200. PubMed ID: 6167620
[TBL] [Abstract][Full Text] [Related]
32. Chimeric and humanized anti-HM1.24 antibodies mediate antibody-dependent cellular cytotoxicity against lung cancer cells.
Wang W; Nishioka Y; Ozaki S; Jalili A; Verma VK; Hanibuchi M; Abe S; Minakuchi K; Matsumoto T; Sone S
Lung Cancer; 2009 Jan; 63(1):23-31. PubMed ID: 18524412
[TBL] [Abstract][Full Text] [Related]
33. Biological activities on T lymphocytes of a baculovirus-expressed chimeric recombinant IgG1 antibody with specificity for the CDR3-like loop on the D1 domain of the CD4 molecule.
Troadec S; Bès C; Chentouf M; Nguyen B; Briant L; Jacquet C; Chebli K; Pugnière M; Roquet F; Cerutti M; Chardès T
Clin Immunol; 2006 Apr; 119(1):38-50. PubMed ID: 16426893
[TBL] [Abstract][Full Text] [Related]
34. Immunomodulatory properties of FK734, a humanized anti-CD28 monoclonal antibody with agonistic and antagonistic activities.
Shiao SL; McNiff JM; Masunaga T; Tamura K; Kubo K; Pober JS
Transplantation; 2007 Feb; 83(3):304-13. PubMed ID: 17297405
[TBL] [Abstract][Full Text] [Related]
35. HuM291, a humanized anti-CD3 antibody, is immunosuppressive to T cells while exhibiting reduced mitogenicity in vitro.
Cole MS; Stellrecht KE; Shi JD; Homola M; Hsu DH; Anasetti C; Vasquez M; Tso JY
Transplantation; 1999 Aug; 68(4):563-71. PubMed ID: 10480417
[TBL] [Abstract][Full Text] [Related]
36. CD137 enhances cytotoxicity of CD3(+)CD56(+) cells and their capacities to induce CD4(+) Th1 responses.
Zhu BQ; Ju SW; Shu YQ
Biomed Pharmacother; 2009 Aug; 63(7):509-16. PubMed ID: 19019623
[TBL] [Abstract][Full Text] [Related]
37. Human T lymphocyte activation by monoclonal antibodies; OKT3, but not UCHT1, triggers mitogenesis via an interleukin 2-dependent mechanism.
Van Wauwe JP; Goossens JG; Beverley PC
J Immunol; 1984 Jul; 133(1):129-32. PubMed ID: 6327822
[TBL] [Abstract][Full Text] [Related]
38. Alloreactivity of ex vivo-expanded T cells is correlated with expansion and CD4/CD8 ratio.
Mercier-Letondal P; Montcuquet N; Sauce D; Certoux JM; Jeanningros S; Ferrand C; Bonyhadi M; Tiberghien P; Robinet E
Cytotherapy; 2008; 10(3):275-88. PubMed ID: 18418773
[TBL] [Abstract][Full Text] [Related]
39. Treatment of lupus patients with a tolerogenic peptide, hCDR1 (Edratide): immunomodulation of gene expression.
Sthoeger ZM; Sharabi A; Molad Y; Asher I; Zinger H; Dayan M; Mozes E
J Autoimmun; 2009 Aug; 33(1):77-82. PubMed ID: 19346102
[TBL] [Abstract][Full Text] [Related]
40. T10B9 (MEDI-500) mediated immunosuppression: studies on the mechanism of action.
Brown SA; Lucas BA; Waid TH; McKeown JW; Barve S; Jackson LR; Thompson JS
Clin Transplant; 1996 Dec; 10(6 Pt 2):607-13. PubMed ID: 8996751
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
